Analyst Francois Brisebois of LifeSci Capital maintained a Buy rating on Avadel Pharmaceuticals, boosting the price target to $22.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Francois Brisebois’s rating is based on several positive developments for Avadel Pharmaceuticals. The recent court decision requiring Avadel to pay a 3.85% royalty on Lumryz sales to JAZZ is seen as a favorable outcome, as it is lower than what many investors anticipated. This decision effectively removes a significant litigation overhang, which is expected to positively impact the stock’s performance.
Additionally, Avadel’s strategic licensing agreement with XWPharma to develop Valiloxybate is expected to broaden its sleep portfolio, further enhancing growth prospects. The company also reported strong financial results for the second quarter of 2025, exceeding revenue expectations and prompting an increase in full-year guidance. These factors, combined with effective commercial investments and improved patient trends, support the Buy rating and suggest continued growth for Avadel Pharmaceuticals.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $36.00 price target.